Clariness supports Covid-19 studies – Clariness

Clariness supports Covid-19 studies

Published by Joseph Yeomans on 26 October 2020

Joseph Yeomans
VP Marketing
[email protected]

26 October, 2020

Hamburg, October 26, 2020. “Clariness is very proud to support patient recruitment of critical Covid-19
studies. We´ve never had such an immediate impact on a disease that affects all of us. Our services
speed up the studies we´re supporting”, says Dr. Andree Beckerling, CEO of Clariness. The
pharmaceutical industry is experiencing difficulty finding Covid-19 positive patients for their clinical

Clariness has spent the past 15 years helping pharmaceutical companies find patients to participate in
their clinical trials. COVID has not stopped us in this endeavour. Rather, it has focused our team
members who are working diligently supporting recruitment efforts to find COVID patients and healthy
volunteers for ongoing clinical trials.

The COVID-19 Pandemic changed everything. We are living in a new normal where social distancing
and mask wearing are de rigour; where quarantining and shutdown of businesses has caused
staggering economic impact. As of mid-October, there have been more than 40 million cases of
COVID-19 reported globally, with a tragic 1.1 million deaths.

The way back to normal is through science and medicine. Researchers around the world are busy
working on vaccines to prevent COVID infection and treatments for patient with the virus. Researchers
and doctors are conducting clinical trials looking at 45 different vaccines to prevent the spread of the
disease. In addition, clinical trials are being conducted to test the efficacy and safety of numerous
compounds, including antivirals, cell & gene therapies, immunomodulators, neutralizing anti bodies and
other treatments. Some of the medicines under study for COVID are older drugs like
hydroxychloroquine, interferon-beta, and ritonavir/lopinavir and newer drugs like Remdesivir.

Currently, there are over 1,000 actively enrolling interventional COVID related studies requiring a total
of 1.3 million volunteers listed on This means that finding patients for a trial is highly
competitive. Making it even more difficult, some protocols have very narrow windows for enrollment of a
patient, for example no longer than 48 hours from first symptoms.
Clariness will continue to contribute driving the development of treatments and preventions to overcome
this pandemic to success


CLARINESS develops and implements a wide array of high-end services to pharma corporations and
CROs in Europe, North America, Latin America and Asia Pacific including patient recruitment, study
feasibility, patient surveys and retention. With 14 years of patient enrollment and engagement
experience as well as their inhouse developed ClinLife® technology, CLARINESS has established
itself as a leading global patient recruitment expert. ClinLife® is the patient portal for clinical trials, live in
50+ countries with more than 28 languages and has been used by thousands of sites.